Trials
Clinical Monotherapy Trial
ESSA is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with mCRPC resistant to standard-of-care treatments.
Collaboration Trials
We are planning to evaluate EPI-7386 in clinical studies in combination with currently approved second-generation antiandrogen therapies as an earlier line of treatment for patients with mCRPC. Based upon preclinical studies, ESSA believes that by inhibiting both the N-terminal domain and the ligand-binding domain, greater suppression of the androgen receptor may result in greater suppression of androgen activity and potentially delay or prevent drug resistance.
